Previous 10 | Next 10 |
2023-03-26 23:52:00 ET Summary Highlightll Pharma out-licensed rights to its novel oral, brain-penetrating, dual inhibitor to New Haven’s Biohaven in a deal worth up to $970 million. F-star, a Cambridge, UK biopharma, out-licensed global rights for a novel next-gen immuno-o...
2023-03-21 10:03:51 ET Gainers: ImmunityBio ( IBRX ) +21% . NuCana ( NCNA ) +16% . Seres Therapeutics ( MCRB ) +14% . SCYNEXIS ( SCYX ) +13% . Corbus Pharmaceuticals ( CRBP ) +12% . Losers: Altimmune ( ALT ) ...
2023-03-21 08:20:25 ET Altimmune ( ALT ) -37% announces positive results from week 24 interim analysis of Pemvidutide MOMENTUM phase 2 obesity trial and 12-Week phase 1b type 2 diabetes safety trial. First Majestic Silver ( AG ) -14% suspends mining at Jerrit...
2023-03-20 13:16:55 ET Connect Biopharma ( NASDAQ: CNTB ) jumped ~19% most in seven months on Monday after presenting pivotal data for its lead candidate CBP-201 in moderate-to-severe atopic dermatitis (AD) at the American Academy of Dermatology Annual Meeting over the wee...
2023-03-20 13:07:07 ET Gainers: Loyalty Ventures ( LYLT ) +97% . Ambipar Emergency ( AMBI ) +73% . Lifecore Biomedical ( LFCR ) +60% . InMed Pharmaceuticals ( INM ) +43% . New York Community Bancorp ( NYCB ) +32% . Harbor Cus...
2023-03-20 10:29:09 ET Gainers: Lifecore Biomedical ( LFCR ) +41% . Connect Biopharma ( CNTB ) +27% . InMed Pharmaceuticals ( INM ) +21% . ReShape Lifesciences ( RSLS ) +21% . Bellerophon Therapeutics ( BLPH ) +15% . Losers...
2023-03-20 08:46:36 ET InMed Pharmaceuticals ( INM ) +29% . New York Community Bancorp ( NYCB ) +27% shines with 30% gain on multiple analyst upgrades amid Signature deal. PacWest Bancorp ( PACW ) +20% . ReShape Lifesciences ( RSLS ) ...
2023-03-19 11:26:12 ET Stock Market Outlook This Week: March 20th – March 24th Whether you’re trading penny stocks or searching for the best high-dividend stocks to invest in for 2023, knowing what to expect in the week ahead could help you understand how to approa...
Late-Breaking Abstract and Oral Presentation at American Academy of Dermatology Annual Meeting Stage 1 of ongoing 52-week China pivotal AD trial met primary and secondary endpoints No efficacy plateau at Week 16 Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect ...
ePoster and Oral Presentation at American Academy of Dermatology Annual Meeting Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage biopharmaceutical company developing T cell-driven therapies to treat inflammatory diseases, ...
News, Short Squeeze, Breakout and More Instantly...
Connect Biopharma Holdings Limited Company Name:
CNTB Stock Symbol:
NASDAQ Market:
Connect Biopharma Holdings Limited Website:
SAN DIEGO, CA and TIACANG, China, July 01, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases thr...
Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting i...